During the #SDPAFall2025 Conference in San Antonio, the HCPLive team interviewed Joseph Gatti, DMSc, MPAS, MBA, PA-C, the founder of The Clinic for Dermatology & Wellness, LLC. He touched on technological shifts in radiology, dermatology, and more...

Two new studies presented at #ACAAI2025 indicated that atopic conditions may increase the risk of post-surgical issues. Read about the studies here: www.hcplive.com/view...#ACAAI2025#Dermatology #AtopicDermatitis #Eczema

ICYMI: New analysis from the DELTA program hints at a striking “super-response” to delgocitinib cream in a notable subgroup with chronic hand #eczema.💡 🌟Durable, meaningful improvements—and even what happened after stopping treatment—are worth a look. 🔗hcplive.com/view/sub...

ICYMI: The American Gastroenterological Association released a clinical practice guideline on the pharmacologic management of Crohn’s disease intended to support a comprehensive, patient-centered, evidence-based approach. Read more: www.hcplive.com/view...

ICYMI: In the latest #SkinofColorSavvy podcast, Drs. Amy McMichael and Kayla Taylor, of @AtriumHealthWFB, spoke on the topic of hair care in patients with skin of color.🎙️ 🔗View more here:

A study presented at #ACAAI2025 reported a link between earlier onset of eczema between 4 to 6 months with a reduced likelihood of outgrowing food allergies. Read more about the findings:

During #AHA2025, we spoke with Julia Grapsa, MD, PhD, to address disparities in aortic stenosis care between male and female patients. Read about how clinicians and investigators alike can improve care quality for women: www.hcplive.com/view...

A special edition episode of Kidney Compass hosted by @BrendonNeuen and @ShikhaWadhwani includes insights on phase 3 telitacicept data, a disease-modifying therapy for IgA Nephropathy. 🩺 Tune in here:

Hear from Naim Alkhouri, MD, Summit Clinical Research, about the importance of differentiating F3 from cirrhosis and the utility of different noninvasive tests for identifying these patients and guiding treatment decisions. Watch now:

Ixekizumab (IXE) may deliver more durable high-level skin clearance among patients living with #psoriasis than several other commonly used biologic drugs, new-real world findings suggest.💡 🔗View more on these findings: www.hcplive.com/view...

A phase 2b trial presented as a late breaker at #ACAAI2025 demonstrates the effectiveness of rezpegaldesleukin, an IL-2 receptor pathway agonist, for the treatment of atopic dermatitis and asthma. Learn more: www.hcplive.com/view...

In the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the significant price drop for Wegovy and Ozempic. These life-changing drugs are now more accessible than ever. Watch now: www.hcplive.com/view/diabete...

New from #AHA2025: We met with James Ip, MD, a professor and cardiologist at Weill Cornell Medicine, about the encouraging efficacy outcomes from several trials of patient-administered etripamil nasal spray in treating PSVT. Watch now:

HCPLive caught up with Emily Becker, MD @UTHealthSA to discuss some of her takeaways from a recent clinic forum discussing how recent impactful additions to the atopic dermatitis treatment landscape have changed practice for the panelists and life for patients. Watch now:

New insight into IgAN treatment landscape: HCPLive spoke with Jurgen Floege, MD, at Kidney Week 2025 about the emerging CD38-targeted therapy, felzartamab for sustained immunologic and symptomatic responses in adults with high-risk IgA Nephropathy. Learn more:

New analysis from the DELTA program hints at a striking “super-response” to delgocitinib cream in a notable subgroup of chronic hand eczema patients. Durable, meaningful improvements—and even what happened after stopping treatment—are worth a look. www.hcplive.com/view...

Donidalorsen continues to show durable, long-term efficacy for #HAE across OASISplus extension and switch data. Check out interview with Daniel Manning, MD, here: www.hcplive.com/view...#HAE#ACAAI2025

New from #AHA2025: We met with Martha Gulati, MD, to discuss the difficulties faced by heart failure patients in understanding and adhering to a significantly burdensome therapy structure. Read our Q&A with Dr. Gulati now: www.hcplive.com/view...

Dapirolizumab pegol, a novel, Fc-free anti-CD40L therapy, continues to demonstrate meaningful patient-centered benefits in systemic lupus erythematosus. Check out what Rosalind Ramsey-Goldman, MD, @northwesternmed, had to say about a new QoL study at #ACR25 now.

Could a controlled metabolic accelerator reshape the future of MASH care? In the following Q&S, Mazen Noureddin, MD, MHSc, breaks down new phase 2 data supporting HU6’s use in MASH: www.hcplive.com/view...

Recent real-world data from the SCALE-UP study show adults with #AtopicDermatitis saw rapid improvements with upadacitinib. ✔️ ~66% saw itch relief ✔️ Strong skin clearance ✔️ Better sleep & QoL 🔗 www.hcplive.com/view...

A phase 2 study, presented as a late breaker at #ACAAI2025, showed povorcitinib improves itch and hives in 3 days among patients with #CSU. Check out this Q&A with Jonathan A. Bernstein, MD @uofcincy: www.hcplive.com/view...#ACAAI2025,#CSU.

New from #AHA: We sat down with Paul Whelton, MD, Show Chwan Health System Endowed Chair in Public Health at Tulane University, to discuss the GMRx2 oral triple combination therapy for hypertension. Watch now:

Rosalind Ramsey-Goldman, MD, @northwesternmed discussed the potential upstream advantages of NAC to safely treat lupus at @ACR2025. Watch now:

Nephrology update: New phase 3 data show telitacicept cut proteinuria by -58.9% vs placebo and stabilized eGFR in high-risk IgAN. More patients hit low-risk UPCR thresholds, with a favorable safety profile. Learn more:

In the latest #SkinofColorSavvy podcast, Drs. Amy McMichael and Kayla Taylor, of @AtriumHealthWFB, spoke on the topic of hair care in patients with skin of color.🎙️ 🔗View more on this discussion here:

New data from the phase 3b ADmirable trial show lebrikizumab effectively treats severe atopic dermatitis in patients with skin of color. Vinay Mehta, MD, breaks down what clinicians need to know at #ACAAI2025: www.hcplive.com/view/lebriki...

New at #AHA2025: We spoke with Viet Le, DMSc, PA-C, from Intermountain Health, to discuss his recent study on the predictive capabilities of atrial fibrillation for MACE in patients with peripheral arterial disease. Read more:

The FDA has accepted Arcutis's supplemental New Drug Application (sNDA) for roflumilast (Zoryve) cream 0.3% in children aged 2-5 years with #psoriasis, potentially expanding the drug’s indication for this age range. 🔗View more here: hcplive.com/view/fda...

Our top trial recaps from #ACAAI2025 are live. From sublingual epinephrine in kids to new #HES, #CSU, #rhinosinusitis, and pediatric #atopicdermatitis data, we break down 4 late-breakers and phase 3 trials shaping #allergy & #immunology care. Read the full coverage here: www.hcplive.com/view...#ACAAI2025#HES,

At #ACAAI2025, Gary Gross, MD, outlined the 2025 coding updates allergists need to know to prevent denials and prepare for 2026. He discusses the new ICD-10 food allergy codes and documentation tips. Read more: www.hcplive.com/view...

Philip Mease, MD, @UWMedicine discussed reaching “state zero” in PsA, which is linked to substantial improvements in pain, function, and overall quality of life at #ACR25. Watch now: www.hcplive.com/view/achievi...

"This is a very good indicator that finenerenone will have durable effects at reducing progression of progressive loss of kidney function in these patients with CKD and T1D," Janet McGill, MD, told HCPLive at #KidneyWk

New at #AHA2025: We sat down with Emily Lau, MD, from Massachusetts General Hospital, to discuss her presentation on the predictive power of cardiorespiratory fitness in pregnancy-related cardiovascular complications. Watch now: www.hcplive.com/view/cardior...

Catch up on the most important headlines in ophthalmology from October with our month in review! From FDA approvals to key trial results, we've chosen 6 headlines from the last month that you won't want to miss. Read now: www.hcplive.com/view...

#ACAAI 2025 begins November 6th in Orlando. HCPLive previews 5 expert interviews and 5 late-breaking trials covering key advancements in #allergy and #immunology, from #PeanutAllergy to #HAE: www.hcplive.com/view...#ACAAI

In new findings, #risankizumab was shown to be an effective and safe treatment of moderate-to-severe #psoriasis in the genital and scalp areas. 🔗View: www.hcplive.com/view...#risankizumab

Skin & brain are in constant conversation, and experts say it’s transforming dermatologic care. Lisa Swanson, MD, Enzo Berardesca, MD, and Mohammad Jafferany, MD, unpack how inflammation links skin disease and mood. www.hcplive.com/view...

At #ACG2025, we spoke with @Marlyn Mayo @UT Southwestern about pooled data from the RESPONSE and ENHANCE studies highlighting seladelpar’s impact on pruritus, one of the most burdensome and debilitating symptoms in PBC. Watch now: www.hcplive.com/view/seladel...

Catch up on the news you might have missed in #cardiology with our month in review! From critical FDA approvals to key trial results, it's been a busy month in cardiovascular care. Read now: www.hcplive.com/view...

Busy October? Catch up on the latest news and updates in GI, including FDA news, long-term data on mirikizumab in ulcerative colitis, the release of an ACP position paper on colorectal cancer screening, and coverage from #ACG2025, in this month in review: www.hcplive.com/view...

With October over, it’s time to recognize #allergy research published last month. Check out this month in review, featuring 6 news, including real-world evidence showing the long-lasting impact of 2015 early food introduction guidelines. www.hcplive.com/view...#allergy

Outlook Therapeutics, Inc., has announced the resubmission of a Biologics License Application for ONS-5010, their investigational VEGF inhibitor, for wet age-related macular degeneration. Read more: www.hcplive.com/view...

The FDA approved doxecitine + doxribtimin, the first therapy for thymidine kinase 2 deficiency, an ultra-rare mitochondrial disorder that causes severe muscle weakness and respiratory failure. Read more:

Exposure to high and low temperatures could have a negative effect on mortality among patients with heart failure, with as many as 2 million deaths annually associated with nonoptimal temperatures. Read more: www.hcplive.com/view...

#PeanutAllergy rates have dropped 27% following AAP’s early introduction guidelines. Investigator Stanislaw Gabryszewski, MD, PhD and Ruchi Gupta, MD, MPH, and Vivian Hernandez-Trujillo, MD weigh in. www.hcplive.com/view...#PeanutAllergy

ICYMI: Adverse pregnancy outcomes - particularly preterm delivery, preeclampsia, and gestational diabetes - have been linked with an increased risk of atrial fibrillation later in life. Read more:

A new real-world study found baked goods with sesame paste led to fewer and milder reactions than raw sesame seeds during oral immunotherapy. 🔗 Read more on HCPLive:

ICYMI: Have you seen our latest feature on JAK inhibitors and their evolution in #dermatology? If not, check out this feature article highlighting the use of JAKis, their safety data, and shifting perceptions. View:

A new meta-analysis finds non-celiac gluten/wheat sensitivity (NCGWS) is more common in women and linked to #IBS, #anxiety, and #depression. #WheatSensitivity 🔗 Read more on HCPLive: